David A. Siegel Century Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $42.8 Billion
- Q1 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Century Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 76,900 shares of IPSC stock, worth $43,064. This represents 0.0% of its overall portfolio holdings.
Number of Shares
76,900
Previous 51,000
50.78%
Holding current value
$43,064
Previous $51,000
29.41%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding IPSC
# of Institutions
69Shares Held
26.9MCall Options Held
12.1KPut Options Held
0-
Bain Capital Life Sciences Investors, LLC Boston, MA5.41MShares$3.03 Million0.87% of portfolio
-
Casdin Capital, LLC New York, NY3.21MShares$1.8 Million0.18% of portfolio
-
Black Rock Inc. New York, NY2.9MShares$1.62 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY2.5MShares$1.4 Million0.29% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.38MShares$1.33 Million0.0% of portfolio
About Century Therapeutics, Inc.
- Ticker IPSC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,881,800
- Market Cap $33M
- Description
- Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...